Advancing Precision Repigmentation Through Real-World Learnings in Vitiligo
- Key outcomes and safety insights from adult and adolescent trials investigating topical JAK inhibition in Vitiligo
- Translating clinical success to pediatric populations and adapting protocols for less extensive disease
- Navigating operational and regulatory challenges including enrollment barriers and long-term data expectations
- Applying lessons from Atopic Dermatitis programs to improve trial design, endpoint strategy, and FDA alignment in Vitiligo